Protein Sciences was founded in 1983 and has over 30 years of experience in developing vaccines and biopharmaceuticals for the prevention and treatment of a variety of diseases. We use our proprietary BEVS protein expression technology to produce high quality recombinant proteins quickly, reliably and at low cost. We have developed three main business lines that employ this technology:
1. Proprietary vaccines - we develop and produce the next generation of safer and more effective vaccines
2. GeneXpress product development and manufacturing services - we partner with others to develop and manufacture modern vaccines, therapeutics and gene therapies
3. Research antigens - we offer a variety of high quality purified antigens and antibodies to the scientific community for disease research
To save lives and improve health by effectively responding to the changing world through the creation of innovative vaccines and biopharmaceuticals.
Our values are core to our culture and guide our every action.
Manon M. J. Cox
President and Chief Executive Officer
Dr. Manon M.J. Cox, MBA has been President and Chief Executive Officer since April 2010, a Director since 2008, and is a member of the Nominating Committee. She joined Protein Sciences in 1998 as Director of Business Development and became Chief Operating Officer in 2003. She serves on the Scientific Advisory Boards of Pall BioPharmaceuticals and iCubed, the Board of Directors of United Way, Meriden & Wallingford, and the Netherlands-America Foundation and its Education Committee. Previously she was with Gist-brocades, a large Dutch company specialized in fermentation, where she held various management positions, most recently in New Business Development and before that in Production and Research and Development. Prior to joining Gist-brocades, she worked as a Molecular Biologist on the development of a PCR screening test for cervical cancer at the University of Amsterdam. Dr. Cox has received many honors and awards recognizing her stature as a leader in innovation and influenza, including in 2014 receiving a Doctorate in Humane Letters honoris causa from St. Joseph University and the Woman of Innovation award from the Connecticut Technology Council. Dr. Cox holds a Doctorate from the University of Wageningen, received her MBA with distinction from the University of Nijenrode and the University of Rochester, NY and holds a Doctorandus degree in Molecular Biology, Genetics and Biochemistry from the University of Nijmegen, The Netherlands.
Daniel D. Adams
Executive Chairman and Global Head of Business Development
Mr. Adams joined Protein Sciences as CEO in 1996. Prior to that time, he founded and managed biopharmaceutical companies that have a combined market value of over $60 billion. Mr. Adams co-founded Biogen (OTC:BGEN) in 1976 and served as its first President and CEO. He also was Founder and CEO of Advanced Genetic Sciences Inc. (OTC:AGSI) in 1980, was Co-founder and Managing Director of Plant Genetic Systems in 1982, and was Founder and CEO of AlleRx in 1989. Mr. Adams is currently a Director of Medivation Inc. and several private companies and medical schools. He received a B.A. from Cornell University (Chemistry and Physics) and earned his J.D., magna cum laude, from New York University School of Law.
Lisa M. Dunkle
Chief Medical Officer
Dr. Dunkle joined Protein Sciences as Chief Medical Officer in 2011 after a 20+ year career in the pharmaceutical industry. As Executive Director of Clinical Research, she previously headed teams at Bristol-Myers Squibb, Schering-Plough and Merck that developed and brought to market several cutting-edge antiviral agents for HIV and HBV. Prior to joining the pharmaceutical industry, Dr. Dunkle was Professor of Pediatrics and Microbiology and Chief of Infectious Diseases at St. Louis University School of Medicine. She has a B.A. in Biological Sciences from Wellesley College and an M.D. from The Johns Hopkins University School of Medicine. She completed post-doctoral work in Pediatrics and Infectious Diseases at Washington University School of Medicine.
Timothy J. Fields
Senior VP, Quality
Mr. Fields joined Protein Sciences in 2010 as Director of Compliance and Training, and subsequently served as Senior Director of Quality Operations before becoming VP of Quality and Validation in 2011. He has more than 30 years of experience in the pharmaceutical industry, including more than 13 years at Pfizer and 16 years as a GMP compliance consultant. Mr. Fields has experience in a variety of compliance areas, including quality systems, validation, aseptic processing, computerized system validation, GMP training, 21CFR Part 11, document management and auditing. He is a member of PDA and ISPE and is on the editorial review board for the Journal of Validation and Journal of GXP Compliance. Previously, he was a member of DIA, RAPS and ASQC and was an adjunct instructor at the Community College of Rhode Island. He has a B.A. in Biology from Indiana University and an M.A. in Life Sciences from Indiana State University.
Mireli W. Fino
Senior VP, Manufacturing Operations
Ms. Fino joined Protein Sciences in 2012 as VP, Manufacturing Operations. She comes from Wyeth (now Pfizer) where she spent the past 20 years in various roles in vaccine development and commercial manufacturing, most recently as Director Manufacturing Sciences and Technology - Drug Substance. She played a key role in the successful development and launch of Prevnar13® pneumococcal 13-valent conjugate vaccine, considered one of the most complex biologics licensed to date. In addition, Ms. Fino led global initiatives implementing process and yield improvements based on the successful applications of risk management and Quality by Design (QbD) and Process Analytical Technology (PAT) concepts. She has a B.S. in Biochemical Engineering from the University of Aguascalientes in Mexico.
Wayne E. Hachey
Head, Government and Clinical Affairs
Wayne Hachey, DO (Colonel, U.S. Army, ret.) is a physician who has dedicated 28 years of service to the military healthcare system, including six years as a subject matter expert advising senior Department of Defense (DoD) leadership regarding the DoD's vaccine policy. He was also responsible for developing the overarching DoD mitigation response to pandemic influenza and directed the implementation of that policy during the 2009 H1N1 pandemic. Most recently, Dr. Hachey served as the Chief of Public Health for the 1st Medical Brigade in Afghanistan, where he provided public health leadership to protect more than 98,000 U.S. troops. Dr. Hachey has a B.A. in Biology from Fitchburg State College, a B.S.N. in Nursing from Boston College, an M.S. in Pediatric Nursing from University of Wisconsin-Madison, an M.P.H. from Uniformed University of the Health Sciences, and a D.O. from Southeastern College of Osteopathic Medicine. He is board certified in Public Health, Pediatrics and Neonatal-Perinatal Medicine and has won numerous awards, including the Defense Meritorious Service Medal, Meritorious Service Medal, NATO (Afghanistan) and Afghanistan Campaign Medal and Unit Combat Patch.
Penny L. Post
Vice President, Regulatory
Dr. Post joined Protein Sciences Corporation in 2000 and has served in various management roles in Process Development, Quality and Manufacturing, becoming Vice President of Regulatory and Quality in 2007 and Vice President of Regulatory in 2011. She has a strong background in biochemistry and protein purification and has been involved in the development, manufacturing, product release and regulatory filing for recombinant proteins involved in various diseases, such as influenza and AIDS. Prior to joining Protein Sciences Corporation, Dr. Post was a Postdoctoral Fellow and Associate Research Scientist at Yale University. She has a B.A. in Biology from Middlebury College, VT and a Ph.D. in Cell Biology and Biochemistry from Carnegie Mellon University.
Indresh K. Srivastava
Vice President, Product Realization
Dr. Srivastava joined Protein Sciences in 2012 as Vice President, Product Realization. He has a strong background in vaccine development, particularly in immunogen design, purification, analytical and formulation development, and has published extensively in these areas. Dr. Srivastava served on the NIH special emphasis study section focused on vaccine development for ten years, and in 2011 he co-edited the book, "Development of Vaccines: From Discovery to Clinical Testing." Previously, Dr. Srivastava spent more than twelve years at Chiron Corporation/Novartis Vaccines and Diagnostics, Inc. in various capacities, including Head (AI), Protein Biochemistry; Head, Vaccine Manufacturing; and Head, Protein Expression and Analytics. He also spent about two years at the Vaccine Research Center, a division of the National Institute of Allergy and Infectious Diseases, where he led the purification, analytical and formulation development of vaccine candidates for clinical evaluation. Prior to joining the biotechnology industry, Dr. Srivastava was an Assistant Professor of Research in Microbiology and Immunology at the Medical College of Pennsylvania. He holds a Ph.D. from the Kanpur University, India and completed his post-doctoral training with Prof. Luc Perrin at the Hospital Cantonal, University of Geneva, Switzerland.
Nadine Francis West
Senior Vice President, Chief Administrative Officer and Corporate Secretary
Ms. West joined Protein Sciences in 2014 as Senior Vice President, Chief Administrative Officer and Corporate Secretary. Previously, she served as Vice President, Chief Administrative Officer and Corporate Secretary and led the Finance and Administration Team of the MetroHartford Alliance. Prior to joining the Alliance, Ms. West served in the administration of former Hartford Mayor Michael Peters and practiced law in the corporate law department of Aetna, Inc. She is a member of the Executive Committee and Chair of the HR/Compensation Committee of the Hartford Stage Company, a Board Member of the UConn Foundation and Achieve Hartford!, a local education fund. Ms. West serves as an overseer of the Bushnell Performing Arts Center and is a Corporator of both Hartford Hospital and Saint Francis Hospital and Medical Center. She is also the interim President of the Board of Upper Albany Main Street. Ms. West was Vice Chair of the Board and Chair of the Development Committee of the Aurora Women and Girls Foundation, Inc. She has also served as Vice Chair of the Board of Directors and Co-Chair of Development of the YWCA for the Hartford Region. Ms. West is a graduate of the U.S. Chamber's Institute of Organization Management and a 2009 Fellow of the Ford Foundation and American Chamber of Commerce Fellowship for Regional and Sustainable Development. She received a BA from SUNY Stony Brook and a JD from the University of Connecticut and is admitted to the Connecticut Bar.
Barry C. Buckland, PhD
Dr. Buckland served as Protein Sciences' Head, BioProcess Development from 2011-2013. Previously, he held a 29-year career at Merck Research Laboratories, including 16 years as Vice President of Bioprocess R&D, during which time vaccines were licensed against chicken pox, shingles, HPV, hepatitis A and rotavirus. In 2009, he became CEO of BiologicB, through which he provides consultancy to companies and non-profit institutions worldwide in all areas of biologics, including vaccines and therapeutic proteins. Dr. Buckland currently serves on the Board of Directors of Ancora Pharmaceuticals and Mucosis BV and is Chair of the Board of Engineering Conferences International. He is also a visiting professor at University College London. He has a B.Sc. in Chemical Engineering from the University of Manchester, UK and a M.Sc. and Ph.D. in Biochemical Engineering from the University College London, UK.
Donna Chandler, PhD
Dr. Chandler is currently an independent consultant for vaccine and biologics development, after more than 28 years of service with the U.S. Food and Drug Administration (FDA) and the U.S. Public Health Service. From 1997 until her retirement in November 2006, she was Deputy Director, Division of Vaccines and Related Products Applications, Office of Vaccines Research and Review, CBER, FDA. Dr. Chandler joined the FDA in 1978, at which time she investigated Mycoplasma pneumoniae pathogenicity and animal models of disease and protection. In 1989, Dr. Chandler moved to the FDA's Division of Biologic INDs, where she was a senior regulatory reviewer of bacterial and viral vaccines, allergenic products and immune globulins.
Thomas Kowalski, Esq.
Mr. Kowalski is a shareholder in Vedder Price PC, a full service law firm, with offices in Chicago, NYC, Washington DC and London. Vedder Price is a general practice firm with a number of significant boutique practices whose reputations are national and international, including its intellectual property practice which handles all aspects of intellectual property law, including patent, trademark, and copyright prosecution, counseling, and litigation, and related matters, including regulatory matters. Mr. Kowalski's practice includes biotech, chemical and medical apparatus litigation, patent prosecution, licensing and counseling. In fulfilling the requirements for American Chemistry Society certification, Mr. Kowalski has extensively studied graduate biochemistry, graduate inorganic chemistry, genetics, computer science and laboratory research.
Deborah Lu, PhD, Esq.
Dr. Lu is a shareholder at Vedder Price PC. Dr. Lu received her B.S. in Biological Sciences with a concentration in Biochemistry from Cornell University, and her M.S. and Ph.D. in Biological Chemistry from the University of Michigan. Dr. Lu was a post-doctoral fellow in Microbiology at Harvard Medical School and in Structural Biology at the Skirball Institute of Biomolecular Medicine at the New York University Medical Center and received her J.D. from Fordham University School of Law.
Peter Patriarca, MD
Vaccine Development and Regulatory Consultant
Dr. Patriarca is a senior consultant with the Biologics Consulting Group, Inc. (Alexandria, Virginia, USA), a full-service consulting firm that provides guidance to industry for all phases of vaccine development. Prior to his current position, Dr. Patriarca was Corporate Head and Vice President, Worldwide Regulatory Affairs and Pharmacovigilance at MedImmune, Inc. from 2001 to 2005. He served as Medical Officer in the U.S. Public Health Service at the Centers for Disease Control and Prevention (CDC) from 1980 to 1992, and at the U.S. Food and Drug Administration (FDA) from 1993 to 2001. Among other positions, Dr. Patriarca served at the FDA as Director of the Division of Viral Products in the Office of Vaccines Research and Review (OVRR), CBER. In that capacity, he worked on the quality and consistency of chemistry, manufacturing and controls and clinical aspects of numerous vaccines and adjuvants, and was intimately involved with regulatory decisions and policy affecting vaccine development and licensure. At the CDC, Dr. Patriarca was assigned to the National Immunization Program, where, in addition to holding other positions, he served as the first head of the CDC's program in support of the global poliomyelitis eradication initiative. He has authored or co-authored more than 100 peer-reviewed publications.
Janet Rea, MSPH, RAC
Advisor, Quality and Compliance Matters
Ms. Rea served as Protein Sciences' Chief Compliance Officer from 2011-2012. Previously, she held the position of Vice President, Regulatory Affairs and Quality at Poniard Pharmaceuticals (previously NeoRx) from 2008 to 2010 and AVI BioPharma from 2003 to 2008, and was a corporate officer for both organizations. Trained as a public health microbiologist at the University of Washington (UW), Ms. Rea started her career with American Dade Division, American Hospital Supply Corporation in Miami, Florida in the microbiology quality assurance group, applying microbiological techniques to improve aseptic processing and reducing product failure. Thereafter, she returned to Seattle, working for Genetic Systems, Immunex (now Amgen), where she played a key role in the approval of the company's first product, LEUKINE; MDS Panlabs, and Targeted Genetics. Her diverse experience transcends the product development continuum in a variety of therapeutic areas, especially oncology, infectious and rare genetic diseases. She is a member of two editorial advisory boards, and has lectured extensively as well as published. She received a Bachelors of Science in Microbiology and was conferred a Masters of Science of Public Health (MSPH) from UW, Seattle, Washington. Ms. Rea is and remains a Clinical Assistant Professor in the Department of Pharmacy at UW, where she has been a frequent lecturer since 1999.
John Treanor, MD
Medical Advisor/ Principal Investigator of Clinical Trials
Dr. Treanor is a Professor of Medicine, Microbiology and Immunology, and Chief of the Division of Infectious Diseases at the University of Rochester Medical Center. He is a current or former member of the Microbiology and Infectious Diseases Research Advisory Committee (MIDRAC), Veteran's Administration Merit Review Board for Infectious Disease, and the CDC's Advisory Committee on Immunization Practice (ACIP). Dr. Treanor's research interests are related to the clinical evaluation of vaccines and other control measures for human infectious diseases, including studies of novel vaccines for seasonal and pandemic influenza, evaluation of antiviral agents for influenza, and studies of the human immune response to influenza infection and vaccination.
Board of Directors
Daniel D. Adams, JD
Mr. Adams has been Executive Chairman of Protein Sciences Corporation since April 2010, having earlier served as President since December 1998 and Chief Executive Officer since May 1996. He was previously a founder, President and Chief Executive Officer of BCCORP LLC, a company involved in taking control of and managing failing biotechnology companies. Mr. Adams also founded and was Chairman of AlleRx Inc. from 1989 to 1993, and was Chief Executive Officer of Advanced Genetic Sciences, Inc. (AGSI) from 1979 to 1986, when it merged with DNA Plant Technologies. He co-founded and was Managing Director of Plant Genetic Systems, N.V. from 1982 to 1989, and co-founded and was President and Chief Executive Officer of Biogen, Inc. (BGEN) from 1976 to 1980.
Dr. Manon M.J. Cox, MBA
Dr. Cox has been President and Chief Executive Officer of Protein Sciences Corporation since April 2010. She joined the company in 1998 as Director of Business Development and became Chief Operating Officer in 2003. Since 2006, she has also served on the Scientific Advisory Board of Pall BioPharmaceuticals. Prior to joining Protein Sciences Corporation, she was employed with Gist-brocades, N.V., a large Dutch company specializing in fermentation. She held various management positions at Gist-brocades, including New Business Development, Production, and Research and Development. She previously worked as a molecular biologist on the development of a PCR screening test for cervical cancer at the University of Amsterdam.
Cheryl L. Cohen
Cheryl L. Cohen was from September 2011 until July, 2014 Chief Commercial Officer of Medivation Inc.(MDVN: NASDAQ). From September 2008 to September 2011, Ms. Cohen was president of CLC Consulting, a pharmaceutical and biotechnology consulting firm specializing in new product start-up and commercialization, where she was responsible for building strategic and tactical plans to ensure successful launches. From1998 to 2007, she worked at Centocor, Inc., a Johnson & Johnson company, in a variety of senior sales roles including vice president, rheumatology franchise, with direct responsibility for the $1+ billion per year Remicade® U.S. rheumatoid arthritis business and its 170-person sales and marketing team. From November 2007-2008 she served as the vice president, strategic commercial group of Health Care Systems, Inc a Johnson & Johnson company where she was directly responsible for access of all the J & J products. Ms. Cohen began her career at Solvay Pharmaceuticals in a variety of sales positions. She received her B.A. from Saint Joseph College.
Cees de Jong, MD, MBA
Dr. de Jong will become the Chief Executive Officer of Chr. Hansen, a global supplier of bioscience-based ingredients to the food, health and animal feed industries, on April 1, 2013.
Dr. de Jong was Chief Operating Officer and a member of the Management Board at Crucell N.V, a publicly traded Netherlands company, from 2007 until its sale in 2011. Crucell's business involved developing and manufacturing vaccines and other products based on PER.C6, a human cell line. Crucell was sold to Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, in 2011 with a value of approximately $3 billion. From 2003 to 2007, Dr. De Jong was Group Vice President and member of the Board at Quest International, ICI, and Business Group Director at Campina and Gist-brocades, N.V. from 2000-2002 and from 1989 to 2000, respectively.
R. Gordon Douglas, MD
Dr. Douglas retired in April 1999 from Merck & Co., where he had been President of the Merck Vaccine Division since 1991 and a member of the Merck Management Committee. Prior to joining Merck, Dr. Douglas was Chairman of the Department of Medicine and Physician-in-Chief at the New York Hospital-Cornell Medical Center. He held earlier teaching, research and administrative posts at the University of Rochester Medical Center and Baylor College of Medicine. Dr. Douglas received his medical staff training at The New York Hospital and Johns Hopkins Hospital, and is board certified in Internal Medicine.
Donna R. Galluzzo, PhD, RD
Since 2003, Dr. Galluzzo has been President and CEO of HMS Healthcare Management Solutions, Inc., a financial support services and consulting organization to healthcare providers such as hospitals, physicians, home care and hospice. Primary services include outsourced billing and collections, revenue cycle management, operational and strategic services, regulatory compliance, education and secure web-based solutions. She was previously President and COO of Connecticut VNA, Inc., one of the largest not-for-profit home health and hospice organizations in the United States. Since 1990, Dr. Galluzzo has owned or been CEO/COO of several healthcare companies that have received multiple awards for excellence and innovation. In addition, she has received numerous awards for her leadership in civic and community boards and activities.
Robert B. Goergen, MBA
Mr. Goergen is Chairman and Chief Executive Officer of Blyth, Inc., a publicly traded firm, and is Managing Partner of The Ropart Group, a private equity firm. Mr. Goergen also is a member and former Chairman of the Board of Trustees of the University of Rochester and a Trustee of the Wharton School at the University of Pennsylvania. He was previously Managing Partner of The Sprout Capital Group at DLJ, Inc.
Howard E. Levine, PhD
Dr. Levine is President and Principal Consultant for BioProcess Technology Consults. Dr. Levine has more than 30 years of experience in successful product companies and as founder of BioProcess Technology Consultants, Inc. Prior to founding BioProcess Technology Consultants, he was Vice President of Manufacturing Operations at Repligen Corporation, where he was responsible for all process development and manufacturing activities, including production of therapeutic proteins, monoclonal antibodies and recombinant Protein A. Dr. Levine was previously Director, Pilot Plant Operations at Xoma Corporation, where he was responsible for the development and manufacture of monoclonal antibody products for clinical trial. He has also held positions in process development and manufacturing at Genentech and Amgen. During the course of his career, he has assisted in the development of more than 25 different biological products and the successful commercialization of three of these products.
Albertus D.M.E. Osterhaus, DVM
Dr. Osterhaus, known as Ab Osterhaus, is an advisor to Artemis Foundation for Wildlife Health Research. He has a long standing track record
as scientific researcher and is an international authority in the field of "Viroscience." Over the years he has been responsible for the
identification of more than 20 novel human and animal viruses, vaccine development and anti-viral drug development against several viruses
including influenza viruses. He has served as member and chairman of many international scientific committees, most notably three WHO reference centers, the Dutch Influenza Centre, the Dutch Health Council and the European Scientific Working group on Influenza (ESWI). He is a member of the Royal Dutch Academy of Arts and Sciences (KNAW). Multiple awards, prizes, guest lecture invitations, organizer of international meetings and editorships of scientific journals highlight his international recognition.